β-catenin/CBP-IN-1 is a potent and selective CBP/β-catenin antagonist, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus.
IC50 & Target: Wnt
Molecular Weight: 658.64
Room temperature in continental US; may vary elsewhere.
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
β-catenin/CBP-IN-1 (intraperitoneal injection;1mg/kg; 42 days) has a treatment effect on liver fibrosis in hepatic fibrosis Cre/loxP/HCV-MxCreTg mouse model.
Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.